Elbe Kliniken Stade-Buxtehude Elbe Klinikum Buxtehude gGmbH — Clinical Trial Site

38 Registered trials

10 Currently recruiting

Organisation

Elbe Kliniken Stade-Buxtehude Elbe Klinikum Buxtehude gGmbH

Location

Buxtehude, Germany

Identifier

ORG-100025859

Address

Am Krankenhaus 1, 21614, Germany

Departments

1006: Klinik für Dermatologie
2169: Klinik fuer Dermatologie
3120: Klinik für Dermatologie
9182: Klinik für Dermatologie
Department of Dermatology
Derma Studien
Dermato- Onkologie
Dermato-Onkologie
Dermato-Onkology
Dermatologie
Dermatologisches Zentrum
Dermatology
Dermatology, Allergology
Hautklinik
Hautkrebszentrum
Hautkrebszentrum Buxtehude
Klinik fur Dermatologie
Klinik für Dermatologie Hautkrebszentrum Buxtehude Dermatologisches Zentrum
N/A
NA
Sektion Dermatologische Onkologie

Clinical trials at this site (38)

Search interface

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended

2022-501966-23-00 Resected High-Risk Stage II Melanoma 5 2018-09-11
A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended

2024-510913-13-00 Previously Untreated Metastatic or Unresectable Melanom 10 2018-05-18
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage… Ended

2023-509136-25-00 Stage III melanoma (AJCC R0) with histologically confir 5 2015-07-16
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29
Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended

2023-504346-66-00 Dermatitis atopic 4 2024-02-14
Clinical trial of MK-7648A in adults and children with skin cancer Ended

2022-501417-31-01 melanoma 5 2023-08-01
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended

2024-511996-13-00 Previously untreated, unresectable, or metastatic melan 5 2022-05-11
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended

2023-507688-20-00 Participants with completely resected Stage III or Stag 5 2021-12-03
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended

2024-510745-34-00 Bullous Pemphigoid 10 2020-11-11
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended

2022-500395-57-00 Resectable high-risk Locally Advanced Cutaneous Squamou 5 2019-03-04
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned… Ended

2025-520468-16-00 Cutaneous Melanoma, Relapsed/Refractory, Locally Advanc 4